{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:45Z","timestamp":1766514165481,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00228-020-02906-z","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T20:10:42Z","timestamp":1591647042000},"page":"1473-1475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6834","authenticated-orcid":false,"given":"I.","family":"Agraz-Pamplona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Larrosa-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. P.","family":"Bury-Macias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ser\u00f3n-Micas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Montoro-Ronsano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"1","key":"2906_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"A Chapman","year":"2015","unstructured":"Chapman A, Devuyst O, Eckardt K, Gansevoort R, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 88(1):17\u201327","journal-title":"Kidney Int"},{"issue":"1","key":"2906_CR2","doi-asserted-by":"publisher","first-page":"c25","DOI":"10.1159\/000334166","volume":"120","author":"M Chang","year":"2012","unstructured":"Chang M, Ong A (2012) Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects. Nephron Clin Pract 120(1):c25\u2013c35","journal-title":"Nephron Clin Pract"},{"key":"2906_CR3","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2016","unstructured":"Devuyst O, Chapman A, Gansevoort R et al (2016) Urine Osmolality, Response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 Trial. J Am Soc Nephrol 28:1592\u20131602","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"2906_CR4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"V Torres","year":"2012","unstructured":"Torres V, Chapman A, Devuyst O, Gansevoort R, Grantham J, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407\u20132418","journal-title":"N Engl J Med"},{"key":"2906_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS (2011) Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 57:692\u2013699","journal-title":"Am J Kidney Dis"},{"unstructured":"Jinarc \u00ae (tolvaptan). Summary of product characteristics. European Agency of Medicines. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jinarc-epar-product-information_en.pdf. Accesed Apr 16th, 2019.","key":"2906_CR6"},{"issue":"1","key":"2906_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3949\/ccjm.83a.14120","volume":"83","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis C, Aggarwal R (2016) Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med 83(1):37\u201342","journal-title":"Cleve Clin J Med"},{"key":"2906_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"C Naranjo","year":"1981","unstructured":"Naranjo C, Busto U, Sellers E et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2906_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","volume":"155","author":"J Woodhead","year":"2016","unstructured":"Woodhead J, Brock W, Roth S, Shoaf S, Brouwer K, Church R, Grammatopoulos TN, Stiles L, Siler SQ, Howell BA, Mosedale M, Watkins PB, Shoda LK (2016) Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci 155(1):61\u201374","journal-title":"Toxicol Sci"},{"key":"2906_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"P Watkins","year":"2015","unstructured":"Watkins P, Lewis J, Kaplowitz N et al (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 38:1103\u20131113","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-02906-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-02906-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:38:14Z","timestamp":1623109094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-02906-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-02906-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}